AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Analyst Meet17-11-2022
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for issuance of Letter of Confirmation in lieu of Duplicate Share Certificate09-11-2022
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Company has received information from Link Intime India Private Limited, Registrar & Share Transfer Agent of the Company for Loss of share certificates07-11-2022
AARTI DRUGS LTD. - 524348 - Compliance Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Compliance under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.02-11-2022
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201502-11-2022
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for issuance of Letter of Confirmation in lieu of Duplicate Share Certificate02-11-2022
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of Q2 FY23 Earning Conference Call31-10-2022
AARTI DRUGS LTD. - 524348 - Scrutinizer'S Report And Voting Results Of The Postal Ballot.
Scrutinizer's report and voting results of the postal ballot.31-10-2022
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Recording of Conference Call21-10-2022
Q2FY23 Quarterly Result Announced for Aarti Drugs Ltd.
Aarti Drugs announced Q2FY23 results: Q2FY23 (Consolidated): Revenue stood at Rs 687.8 crores as against Rs 579.7 crores, a growth of 19% YoY. EBITDA stood at Rs 74.3 crores as against Rs 73.8 crores YoY. EBITDA Margin (%) came in at 10.8%. PAT stood at Rs 38.7 crores as against Rs 42.6 crores YoY. PAT Margin (%) stood at 5.6%. H1FY23 (Consolidated): Revenue stood at Rs 1,310.0 crores as against Rs 1,161.3 crores, a growth of 13% YoY. EBITDA stood at Rs 141.7 crores as against Rs 155.1 crores YoY. EBITDA Margin (%) came in at 10.8%. PAT stood at Rs 73.5 crores as against Rs 91.4 crores YoY. PAT Margin (%) stood at 5.6% Commenting on the results Mr. Adhish Patil, Chief Financial Officer – Aarti Drugs Limited said, “The company achieved healthy growth despite the geopolitical uncertainties, adverse currency movement and macro-economic volatilities, led by higher realizations in APIs and Specialty Chemicals. The quarter witnessed the highest-ever realizations for most of the API products along with moderation in input costs. We firmly believe that there is a potential for further moderation in the quarters, which in turn can expand the margin profile of the company. The company witnessed a marginal increase in OPEX due to upward movement in power and fuel costs along with one-time arrears paid to the employees and Labour contractors. Further, the finance cost was slightly impacted due to higher working capital requirements and even theinterest rat e has gone up in the quarter. Nevertheless, the business is optimistic about attaining its growth and margin goals on the back of higher efficiency and falling raw material prices. Revenue from the formulation segment totalled Rs 82.5 crores for the quarter, up 9% YoY. The formulation segment's share of the total revenue for the quarter was 12%. The formulation segment's core focus area remained exports. During the quarter, exports contributed 44% of the total revenue. Specialty Chemicals, Intermediates & Others continues to be a key enabler for growth of the company. The growth in this segment is mainly driven by the niche Chlorosulphonation products along with recently augmented capacity. The company will focus to further enhance the market share for this segment. The capex for H1FY23 stood at Rs 77 crores and is expected to be in the range of Rs 200-300 crores for the entire FY23. The civil construction activity has picked up the pace for Gujarat capex which was impacted due to heavy monsoon during H1FY23. Tarapur specialty chemicals brownfield capacity which had taken scale-up batches earlier have now been ramped up and expected to contribute to the topline meaningfully from Q3FY23 onwards. Tarapur greenfield API capex is also expected to be completed within its timeline. These capex initiatives, funded through an optimal mix of debt and internal accruals are expected to drive the growth across segments along with improvement in profitability and market share. The company remains optimistic about the prospects for all the segments. In the following years, the growth trajectory for all segments is anticipated to remain solid, driven by incremental capacity addition and higher utilisation of existing capacities.” Result PDF21-10-2022